Intercept Pharmaceuticals Stock News

Intercept (ICPT) delivered earnings and revenue surprises of 2.38% and 0.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome

Intercept Pharma press release (ICPT): Q4 GAAP EPS of -$1.23 misses by $0.18.Revenue of $92.4M (+11.1% Y/Y) beats by $0.31M.Company provides 2022 Ocaliva net sales guidance of…

These two biotech stocks already have blockbuster therapies that are driving increased revenue.

Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year

Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2021 Results - Earnings Call Transcript

Intercept (ICPT) delivered earnings and revenue surprises of 2.38% and 0.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • SIGNA Sports United (NYSE: SSU ) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. • IsoPlexis (NASDAQ: ISO ) is likely to report quarterly loss at $0.68 per share on revenue of $5.45 million. • Innoviz Technologies (NASDAQ: INVZ ) is likely to report quarterly loss at $0.18 per share on revenue of $2.93 million. • International Seaways (NYSE: INSW ) is expected to report quarterly loss at $0.36 per share on revenue of $102.60 million. • Dine Brands Global (NYSE: DIN ) is estimated to report quarterly earnings at $1.27 per share on revenue of $236.67 million. • Dollar Tree (NASDAQ: DLTR ) is expected to report quarterly earnings at $1.77 per share on revenue of $7.12 billion. • Valens Semiconductor (NYSE: VLN ) is projected to report quarterly loss at $0.06 per share on revenue of $20.04 million. • Sterling Check (NASDAQ: STER ) is projected to report quarterly earnings at $0.17 per share on revenue of $152.50 million.

These two biotech stocks already have blockbuster therapies that are driving increased revenue.

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharma (NASDAQ:ICPT) is scheduled to announce Q4 results on Wednesday, Mar. 2, before market open.Consensus EPS estimate is -$0.81 and consensus revenue estimate is $92.09M

NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to trea

NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021 financial results prior to market open on Wednesday, March 2, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.